Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

401 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Acute myeloid leukemia with translocation (8;21). Cytomorphology, dysplasia and prognostic factors in 41 cases. AML Cooperative Group and ECOG.
Haferlach T, Bennett JM, Löffler H, Gassmann W, Andersen JW, Tuzuner N, Casslleth PA, Fonatsch C, Schoch C, Schlegelberger B, Becher R, Thiel E, Ludwig WD, Sauerland MC, Heinecke A, Büchner T. Haferlach T, et al. Among authors: buchner t. Leuk Lymphoma. 1996 Oct;23(3-4):227-34. doi: 10.3109/10428199609054825. Leuk Lymphoma. 1996. PMID: 9031103 Clinical Trial.
Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial.
Kern W, Haferlach T, Schoch C, Loffler H, Gassmann W, Heinecke A, Sauerland MC, Berdel W, Buchner T, Hiddemann W. Kern W, et al. Among authors: buchner t. Blood. 2003 Jan 1;101(1):64-70. doi: 10.1182/blood-2002-02-0532. Epub 2002 Jun 28. Blood. 2003. PMID: 12393605 Free article. Clinical Trial.
Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies.
Haferlach T, Schoch C, Löffler H, Gassmann W, Kern W, Schnittger S, Fonatsch C, Ludwig WD, Wuchter C, Schlegelberger B, Staib P, Reichle A, Kubica U, Eimermacher H, Balleisen L, Grüneisen A, Haase D, Aul C, Karow J, Lengfelder E, Wörmann B, Heinecke A, Sauerland MC, Büchner T, Hiddemann W. Haferlach T, et al. Among authors: buchner t. J Clin Oncol. 2003 Jan 15;21(2):256-65. doi: 10.1200/JCO.2003.08.005. J Clin Oncol. 2003. PMID: 12525517
The role of GM-CSF in the treatment of acute myeloid leukemia.
Büchner T, Hiddemann W, Wörmann B, Rottmann R, Maschmeyer G, Ludwig WD, Zühlsdorf M, Buntkirchen K, Sander A, Aswald J, et al. Büchner T, et al. Leuk Lymphoma. 1993;11 Suppl 2:21-4. doi: 10.3109/10428199309064257. Leuk Lymphoma. 1993. PMID: 8124228 Clinical Trial.
The significance of trisomy 8 in de novo acute myeloid leukaemia: the accompanying chromosome aberrations determine the prognosis. German AML Cooperative Study Group.
Schoch C, Haase D, Fonatsch C, Haferlach T, Löffler H, Schlegelberger B, Hossfeld DK, Becher R, Sauerland MC, Heinecke A, Wörmann B, Büchner T, Hiddemann W. Schoch C, et al. Among authors: buchner t. Br J Haematol. 1997 Dec;99(3):605-11. doi: 10.1046/j.1365-2141.1997.4473257.x. Br J Haematol. 1997. PMID: 9401073 Free article.
401 results